Anteris Technologies GlobalASX:AVR +10.05%50 EBITDA Margin % is -4,443.04% as of Mar. 2026. GuruFocus rates ASX:AVR with a GF Score™ of 50/100. The stock has 7 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Anteris Technologies Global ranks worse than 97.3% on this metric.
Anteris Technologies Global (ASX:AVR) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Anteris Technologies Global EBITDA Margin % Related Terms
Anteris Technologies Global EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:AVR vs INMD, QDEL, SSII: EBITDA Margin % Comparison
For the Medical Devices subindustry, Anteris Technologies Global's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anteris Technologies Global EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Anteris Technologies Global's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Anteris Technologies Global's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anteris Technologies Global (ASX:AVR) has a EBITDA Margin % of -4,443.04% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anteris Technologies Global and its competitors. According to the industry distribution chart, Anteris Technologies Global ranks #794 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 97.3%.
Is Anteris Technologies Global's EBITDA Margin % too high?
Anteris Technologies Global's current EBITDA Margin % is -4,443.04%. Based on the distribution chart, Anteris Technologies Global ranks #794 out of 816 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Anteris Technologies Global has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Anteris Technologies Global's EBITDA Margin % compare to INMD and QDEL?
According to the Medical Devices & Instruments industry distribution chart, Anteris Technologies Global ranks #794 out of 816 companies for EBITDA Margin %. This places Anteris Technologies Global in the lower half of its industry. The industry median EBITDA Margin % is 7.48. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.48, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Anteris Technologies Global and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.48 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anteris Technologies Global's current EBITDA Margin % is -4,443.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anteris Technologies Global stock overvalued right now?
Anteris Technologies Global (ASX:AVR) has a current EBITDA Margin % of -4,443.04%. The current EBITDA Margin % is -4,443.04%. Anteris Technologies Global's overall GF Score™ is 50/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Anteris Technologies Global (ASX:AVR), the current EBITDA Margin % is -4,443.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anteris Technologies Global Corp is a structural heart company focused on advancing cardiac care through science-driven innovations aimed at restoring heart valve patients to healthy function. Its key product, the DurAVR Transcatheter Heart Valve (THV), was designed in partnership with interventional cardiologists and cardiac surgeons to treat Aortic Stenosis, a potentially life-threatening condition caused by narrowing of the aortic valve. The balloon-expandable DurAVR THV is a biomimetic valve designed to mimic the performance of a healthy human aortic valve and replicate normal aortic blood flow. The company operates in United States, Germany, Australia, Switzerland, and Sweden, with the majority of its revenue generated from the United States.
50GF Score
Get the complete analysis for ASX:AVR
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:AVR has been successfully added to your 
